3 Inhaled aerosols as carriers of pulmonary medicines and the limitations of in vitro–in vivo correlation (IVIVC) methods
-
Tomasz R. Sosnowski
and
Arkadiusz K. Kuczaj
Abstract
Pulmonary drug delivery (PDD) involves flow and deposition of aerosol particles acting as carriers of drugs delivered onto the surface of the airways. As a direct consequence, optimal PDD requires controlling of drug aerosolization processes and deep understanding of multiphase flows in complex geometry of the airways including aerosol particle dynamics during the transient inhalation cycles. A chemical engineering-based approache can be effectively used to analyze these processes and help in designing optimized drug formulations and more effective drug delivery devices (inhalers). One of prerequisites of improved PDD is the knowledge of in vivo–in vitro correlation (IVIVC) for inhaled drugs that would allow establishment of the relationships between aerosol quality determined using ex vivo methods (such as determination of particle size, deposition in reconstructed anatomical structures, pharmacokinetics/pharmacodynamics using in vitro cellular systems, or in silico modeling of aerosol dynamics) in connection to the clinical effects. This manuscript discusses the challenges of the IVIVC analyses for aerosol delivery systems. The primary focus is given to the physical and physicochemical constraints in the PDD that can be effectively described and investigated using engineering approaches.
Abstract
Pulmonary drug delivery (PDD) involves flow and deposition of aerosol particles acting as carriers of drugs delivered onto the surface of the airways. As a direct consequence, optimal PDD requires controlling of drug aerosolization processes and deep understanding of multiphase flows in complex geometry of the airways including aerosol particle dynamics during the transient inhalation cycles. A chemical engineering-based approache can be effectively used to analyze these processes and help in designing optimized drug formulations and more effective drug delivery devices (inhalers). One of prerequisites of improved PDD is the knowledge of in vivo–in vitro correlation (IVIVC) for inhaled drugs that would allow establishment of the relationships between aerosol quality determined using ex vivo methods (such as determination of particle size, deposition in reconstructed anatomical structures, pharmacokinetics/pharmacodynamics using in vitro cellular systems, or in silico modeling of aerosol dynamics) in connection to the clinical effects. This manuscript discusses the challenges of the IVIVC analyses for aerosol delivery systems. The primary focus is given to the physical and physicochemical constraints in the PDD that can be effectively described and investigated using engineering approaches.
Chapters in this book
- Preface V
- List of contributing authors
-
Part I Chemical engineering and medicine
- 1 A systems engineering approach to medicine 3
-
Part II Modelling physiology
- 2 Computational modelling in liver system and liver disease 21
- 3 Inhaled aerosols as carriers of pulmonary medicines and the limitations of in vitro–in vivo correlation (IVIVC) methods 49
- 4 Modelling drug permeation across the skin: a chemical engineering perspective 73
- 5 Chemical engineering contribution to hemodialysis innovation: achieving the wearable artificial kidneys with nanomaterial-based dialysate regeneration 103
-
Part III Disease and treatment
- 6 Precision medicine in hypothyroidism: an engineering approach to individualized levothyroxine dosing 127
- 7 Glucose sensors in medicine: overview 167
- 8 Macroscopic transport models for drugs and vehicles in cancer tissues 185
- 9 Mathematical modelling of hollow-fiber haemodialysis modules 203
- 10 Chemical engineering methods in better understanding of blood hydrodynamics in atherosclerosis disease 243
- 11 On the development of pharmacokinetic models for the characterisation and diagnosis of von Willebrand disease 263
-
Part IV Pharmacokinetics and drug delivery
- 12 An introduction to quantitative systems pharmacology for chemical engineers 293
- 13 A novel strategy for brain cancer treatment through a multiple emulsion system for simultaneous therapeutics delivery 315
- 14 Model-based dose selection for gene therapy for haemophilia B 333
- 15 Lipid-based nanoparticles for nucleic acids delivery 359
- Index
Chapters in this book
- Preface V
- List of contributing authors
-
Part I Chemical engineering and medicine
- 1 A systems engineering approach to medicine 3
-
Part II Modelling physiology
- 2 Computational modelling in liver system and liver disease 21
- 3 Inhaled aerosols as carriers of pulmonary medicines and the limitations of in vitro–in vivo correlation (IVIVC) methods 49
- 4 Modelling drug permeation across the skin: a chemical engineering perspective 73
- 5 Chemical engineering contribution to hemodialysis innovation: achieving the wearable artificial kidneys with nanomaterial-based dialysate regeneration 103
-
Part III Disease and treatment
- 6 Precision medicine in hypothyroidism: an engineering approach to individualized levothyroxine dosing 127
- 7 Glucose sensors in medicine: overview 167
- 8 Macroscopic transport models for drugs and vehicles in cancer tissues 185
- 9 Mathematical modelling of hollow-fiber haemodialysis modules 203
- 10 Chemical engineering methods in better understanding of blood hydrodynamics in atherosclerosis disease 243
- 11 On the development of pharmacokinetic models for the characterisation and diagnosis of von Willebrand disease 263
-
Part IV Pharmacokinetics and drug delivery
- 12 An introduction to quantitative systems pharmacology for chemical engineers 293
- 13 A novel strategy for brain cancer treatment through a multiple emulsion system for simultaneous therapeutics delivery 315
- 14 Model-based dose selection for gene therapy for haemophilia B 333
- 15 Lipid-based nanoparticles for nucleic acids delivery 359
- Index
